Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 197 participants.

Also called NCT01313572

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 197 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01313572
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Belgium, Brazil, Netherlands (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01313572. Randomized; triple masking; primary purpose diagnostic. Start 2011-08 (registry gives no type); primary completion 2012-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
Acronym
ASPECT2
Intervention (Drug)
Apadenoson SPECT-MPI
Intervention (Drug)
Adenosine SPECT-MPI
Lead sponsor
Forest Laboratories (class: industry)
Collaborator
PPD Development, LP (class: industry)

Record details

Record id
cardio:ct-nct01313572
Content hash
7247652d64087c943c40ffe557bb2d521df2cdbf7cef162dd1b97e5f89ff0015